News

News

Alertgy Appoints Seasoned MedTech Executive Ruba Sarris Sawaya as Senior Advisor for Quality, Regulatory & Clinical Affairs.

by Alertgy

Melbourne, FL and Houston, TX – September 30, 2023 – Alertgy, a pioneering force in diabetes technology, is pleased to announce the appointment of Ruba Sarris Sawaya as a Senior Advisor for Quality, Regulatory & Clinical Affairs.

With a remarkable career in medtech, including roles as the Chief Scientific Officer at TYBR Health, Executive Vice President of Clinical Affairs at Don Joy Orthopedics, Director of GCORE (Government Affairs, Clinical Affairs & Center for Outcomes Research, Reimbursement & Evaluation) at Orthofix, and multiple senior leadership positions within Medtronic’s Restorative Therapies Group, Mrs. Sawaya brings a wealth of corporate strategy expertise and a track record of high-impact regulatory, clinical, and reimbursement initiatives enabling successful device commercialization and market access. Her vast experience and proven leadership will be instrumental in advancing Alertgy’s diabetes device technology and ensuring the highest standards of quality, regulatory compliance, and clinical excellence.

“We are excited to welcome Ruba and look forward to working with her on the next stage of Alertgy’s growth. We feel that she will be an indispensable asset as we continue to chart our regulatory path.” John Hubert Interim CEO/COO.

About Alertgy: Alertgy stands as a trailblazer in the realm of Non-Invasive continuous blood glucose monitoring (CGM) technologies. At the heart of its mission is development of DeepGluco™, an integrated continuous glucose monitor enriched with a patented sensor and powerful proprietary AI algorithms that’s poised to redefine diabetes management by merging cutting edge technology with a user-centric design.

For more information please contact:

John Hubert

Interim CEO/COO john.hubert@alertgy.com

Mark Semler Appointed as The New Chief Executive Officer of Alertgy

by Alertgy

Melbourne, FL and Charleston, SC

Alertgy, a leader in 100% non-invasive, continuous glucose monitoring (CGM) technology announced today the appointment of Mark Semler as its new CEO. Mr. Semler brings over 20 years of experience in the medical device industry as an executive, R&D leader, and engineer. Before joining Alertgy, he was CEO of ZIAN, a technology accelerator for the Medical University of South Carolina, where his team selected innovative technologies, got funding, developed them, and licensed them to industry. Before ZIAN, Mark was the VP of R&D for Orthofix’s $140M spinal implants division, leading a 30-member team of engineers and designers in the end-to-end development and commercialization of dozens of novel spinal implant systems. Mr. Semler began his career at Boston Acoustics before transitioning to medical devices.

Mark Semler stated: “I am honored to be a part of the Alertgy mission. What Marc Rippen and his team have created over the last five years has the potential to make a big impact on the world. 

This is an amazing technology, and the company has been extremely efficient with capital. Their progress on each generation of the technology has put us in a good position to move this through development and into clinical trials. We will be moving into a new phase and I look forward to working with and growing the team.”

Mr. Marc Rippen, founder, chairman of the board and outgoing CEO stated: “We are thrilled to welcome Mark. His multifaceted background will be instrumental in taking Alertgy to the next phase of medical device development and commercialization. His strong industry network will help complete the current and initiate future rounds of funding as well as onboard new industry talent in key financial, quality, regulatory, marketing and engineering areas. I look forward to working with Mark and making DeepGluco™ a reality for hundreds of millions of diabetic patients and individuals with borderline diabetes, which may grow into the billions worldwide.”

Mr. Rippen will continue to chair Alertgy’s board, and as Chief Innovation Officer will focus on completing the current generation device for continued clinical testing.

About Alertgy:  Alertgy is a pioneer in 100% non-invasive continuous blood glucose monitoring (CGM) technology. Using a patented radio frequency sensor, Alertgy’s DeepGluco™R&D is currently validating a wearable device with the goal that it will accurately measure blood glucose in real time, up to 3 times per minute. Most importantly, using a proprietary AI algorithm, DeepGluco™ strives to provide invaluable, up to the minute life-saving alerts to patients, their families, and designated HCPs. Unlike other CGMs, DeepGluco™’s noninvasive design hopes to eliminate interstitial lag and avoid the painful and uncomfortable side effects of expensive and invasive patches, needles, and implants. The final DeepGluco™ form factor will be a modern smart watch, available to consumers following FDA and CE approvals.

 

For more information please contact:

Tanya Coker

Director of Marketing Strategy  

tanya@alertgy.com

Alertgy Takes Home Third Place In Luminate NY Optics, Photonics, And Imaging Startup Accelerator Competition

by Alertgy

Optics and photonics startup Alertgy Inc. which has developed the world’s first non-invasive glucometer on the market took home the third-place prize of $250,000 in the latest Luminate NY accelerator competition, which was held this week at NYU Polytechnic School of Engineering’s MetroTech Center in Brooklyn.

What is Alertgy?

Alertgy is the world’s first non-invasive glucometer on the market using dielectric spectroscopy and artificial intelligence. Glucometers have been around since the 1920s and are a staple in diabetes management. However, all traditional glucometers require at least a finger prick to take a blood sample, which can be painful and is not real-time.

The Road to Luminate NY

We were recently selected to participate in the cohort of Luminate NY’s accelerator program. The four-month program provides a hands-on curriculum with expert instruction on all aspects of starting and scaling a business in the optics, photonics and imaging industry. Most importantly, it gave us access to mentors who are at the top of their game. They have connections in industries we never even knew existed – from manufacturing supply chains to design software developers! During this time, we’ve been hard at work building our team and creating prototypes for potential markets.

Luminate NY optics, photonics, and imaging startup accelerator competition.

Luminate NY is a startup accelerator program for optics, photonics and imaging startups. The three-month business intensive offers funding and expert mentorship to entrepreneurs with innovations in these fields. Alertgy was selected as one of the nine companies in this year’s cohort and took home third place after a judging panel from industry experts ranked them against their peers.

Read Article on Luminate

Alertgy Takes Top Prize International DxPx Conference Competition

by Alertgy
November 16, 2021

Melbourne, Florida and Dusseldorf, Germany –   Alertgy, a pioneer in 100% non-invasive continuous blood glucose monitoring won first place for the most disruptive medical technology in 2021 at a recently held DxPx Conference in Dusseldorf, Germany.  Prior to this award, Alertgy secured top spot in DxPx’ North American competition. The prize, valued between $500,000 and $1,000,000 was sought by 237 applicants and 8 finalists globally.

According to Marc Rippen, Alertgy’s CEO and Founder, “This global recognition and monetary prize will allow our company to accelerate the speed of clinical trials in the US and Europe, develop the next generation device, and hire top-level medtech talent to take us to the next level.   We are extremely excited and proud of what we’ve been able to accomplish in the last 4 years and DxPx is a validation of our efforts.   We are looking forward to commercializing our glucometer and helping hundreds of millions of patients worldwide afflicted with diabetes as well as the ever-growing pre-diabetic population”.

Through the use of its patented radio frequency sensor, Alertgy’s DeepGluco wearable device is able to accurately measure blood glucose in real-time, up to 3 times per minute.  Most importantly, using proprietary AI algorithm, DeepGluco can provide invaluable, up-to-the-minute life-saving alerts to the users, their families and endocrinologist.  Unlike other CGMs, DeepGluco eliminates interstitial lag as well as painful and uncomfortable side effects of patches, needles, and implants. The final DeepGluco form factor will be similar to modern smart watches, available to consumers following FDA and CE Mark approvals in 2024.

For more information on Alertgy please visit: www.Alertgy.com
To gain access to our non-confidential company deck and other materials please contact:

Tanya Coker
Director of Marketing and Communications
2412 Irwin Street
Melbourne, FL 32901
tanya@alertgy.com
Improving Diabetic Health Through Innovation

Learn More about
42PLUS1 US Satellite Award Winner –Alertgy

 

Watch Video

Alertgy Inc. Secures Developer Agreement with SEMI’s FlexTech

by Daniel Masteller

Alertgy Inc. is pleased to announce that it has been awarded the following Developers Agreement between Alertgy Inc. and SEMI – Flextech. SEMI is the global industry association representing the electronics manufacturing supply chain, connecting over 2,000 member companies and 1.3 million professionals worldwide. FlexTech is SEMI’s Technology Community focused on the growth, profitability and success of flexible and printed electronics. Community activities include organizing collaboration opportunities, directing research and development funding and advocating for the technology.

 

“Alertgy is honored to begin new development partner relationships with Flextech members. Through these relationships, Alertgy and its partners will work to solve challenges faced by civilians and military personnel. A Flexible Hybrid Electronic Wristband Sensor Platform will be developed to allow for non-invasive blood glucose monitoring, along with other sensing functionality for military personnel,” says Alertgy CEO Marc Rippen.

 

Alertgy Inc., a company founded in Melbourne, FL, is making non-invasive blood glucose monitoring technology accessible to diabetics around the world. With its revolutionary technology, Alertgy is committed to improving the lifespan, quality of life, and effectiveness of medical treatment for millions of diabetics.

Alertgy wins Nasa iTech Inight the Night Orlando

by Daniel Masteller

 

Alertgy took home first prize in the Nasa iTech Ignite the Night Orlando competition, and event to find new and upcoming technologies that could improve the future of space exploration and life on earth. Ten companies from all over the world presented to a panel of judges to earn a semifinalist slot in the current Nasa iTech Cycle, and eventually a finalist spot in the forum in Las Vegas.  Alertgy will now present in the semi finals with 10 other companies in Las Cruces, New Mexico on Otober 7-8.

 

https://www.nasaitech.com/blog/ten-finalist-companies-to-present-in-new-mexico

Letter from Orlando Mayor Buddy Dyer

by Daniel Masteller

 

Ahead of The Rise of the Rest competition in Orlando, Alertgy was sent a congratulatory letter by Orlando Mayor Buddy Dyer. We were extremely proud to be named as one of the finalists for the competition, and thank Orlando and Mayor Dyer for being so welcoming.

Alertgy Wins $15,000 Prize In FAU Pitch Deck Competition

by Daniel Masteller

 

Florida Atlantic University held their third installment of their pitch deck competition for start-up companies. Competing against various other start-ups, Alertgy took home 1st place, along with a $15,000 prize. This was an amazing opportunity for Alertgy to gather even more name recognition and bring our revolutionary technology into the mainstream!

Alertgy is currently in clinical trials.